Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents

Coronary Artery Disease

Volumn 22, Issue 1, 2011, Pages 12-17

  Park, Hun Jun ^a   Seo, Suk Min ^a   Shin, Woo Seung ^b   Kim, Hee Yeol ^c   Choi, Yoon Seok ^d   Koh, Yoon Seok ^b   Youn, Sung Gyu ^e   Park, Mahn Won ^e   Chang, Kiyuk ^a   Kim, Pum Joon ^a   Jung, Hae Ok ^a   Baek, Sang Hong ^a   Chung, Wook Sung ^a   Seung, Ki Bae ^a   Yoo, Ki Dong ^f  

^a The Catholic University of Korea   (South Korea)

^b Uijeongbu St Mary's Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Bucheon St Mary's Hospital   (South Korea)

^e St Mary's Hospital   (South Korea)

^f The Catholic University of Korea   (South Korea)

Author keywords

drug eluting stent; restenosis; soluble receptor for advanced glycation end products; type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; GLYCOSYLATED HEMOGLOBIN; SOMATOMEDIN C;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RESTENOSIS;

AGED; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RESEARCH DESIGN; RISK FACTORS;

EID: 78650775865     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328340b210     Document Type: Article

References (37)

1. Elezi S, Kastrati A, Pache J,Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes mellitus and clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32:1866-1873. (Pubitemid 29010448)
2. Feld S, Almagor Y, Vaughn WK, Leon MB, Serruys PW. Predictors of clinical outcomes following NIR stent implantation for coronary artery disease: Analysis of the results of the First International New Intravascular Rigid-Flex Endovascular Stent Study (FINESS trial). J Interv Cardiol 2002; 15:1-6.
3. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008; 51:708-715.
4. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005; 112:2175-2183.
5. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007; 154:688-693.
6. Frobert O, Lagerqvist B, Carlsson J, Lindback J, Stenestrand U, James SK. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: A report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009; 53:1660-1667.
7. Rathore S, Terashima M, Katoh O, Matsuo H, Tanaka N, Kinoshita Y, et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. Eurointervention 2009; 5:349-354.
8. Welt F, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22:1769-1776.
9. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol 2006; 59:232-239.
10. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90:439-446.
11. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res 2000; 86:125-130.
12. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004; 24:435-444.
13. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-1321.
14. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, et al. RAGE: A novel cellular receptor for advanced glycation end products. Diabetes 1996; 45:s77-s80.
15. Aronson D. Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses 2002; 59:297-301.
16. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, et al. Receptor for AGE (RAGE) mediates neointima formation in response to arterial injury. Circulation 2003; 107:2238-2243.
17. Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular disease. Mol Med 2007; 13:625-635.
18. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007; 8:1138-1143. (Pubitemid 47578142)
19. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007; 13:185-189. (Pubitemid 46944961)
20. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007; 23:368-371.
21. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 2008; 76:52-56.
22. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study Group. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: The EURODIAB Prospective Complications Study. Diabetologia 2009; 52:705-714.
23. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005; 28:2716-2721.
24. Katakami N, Kaneto H, Matsuhisa M, Yamasaki Y. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 2007; 190:22-23.
25. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009; 204:288-292.
26. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, et al. N (epsilon)- (carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathway and modulate gene expression. J Biol Chem 1999; 274:31740-31749.
27. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43:15-17.
28. Lindsay J, Sharma AK, Canos D, Nandalur M, Pinnow E, Apple S, et al. Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C. Cardiovasc Revasc Med 2007; 8:15-20.
29. Lemesle G, Bonello L, De Labriolle A, Maluenda G, Syed AI, Collins SD, et al. Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. Am J Cardiol 2009; 104:41-45.
30. Skowasch D, Jabs A, Andrie R, Luderitz B, Bauriedel G. Progression of native coronary plaques and in-stent restenosis are associated and predicted by increased pre-procedural C reactive protein. Heart 2005; 91:535-536.
31. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37:839-846.
32. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003; 114:715-722.
33. Rittersma SZ, De Winter RJ, Koch KT, Schotborgh CE, Bax M, Heyde GS, et al. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem 2004; 50:1589-1596.
34. Dibra A, Ndrepepa G, Mehilli J, Dirschinger J, Pache J, Schuhlen H, et al. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. Am J Cardiol 2005; 95:1238-1240.
35. De la Torre-Hernandez JM, Sainz-Laso F, Burgos V, Perez T, Figueroa A, Zueco J, et al. Comparison of C-reactive protein levels after coronary stenting with bare metal versus sirolimus-eluting stents. Am J Cardiol 2005; 95:748-751.
36. Park DW, Lee CW, Yun SC, Kim YH, Hong MK, Kim JJ, et al. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart 2007; 93:1087-1092.
37. Kang WC, Ahn TH, Moon CI, Han SH, Shin EK, Kim JS, et al. Comparison of inflammatory markers and angiographic outcomes after implantation of Rapamycin and Paclitaxel-Eluting Stents. Heart 2009; 95:970-975.